Sermorelin: the complete research guide.

Sermorelin is the original GHRH analog. It used to have FDA approval. Today it doesn't, and the adult-use data is thin.

What is sermorelin?

Sermorelin is a synthetic copy of the first 29 amino acids of native GHRH. The full hypothalamic peptide is 44 residues long. The first 29 carry the entire receptor-binding region, so this short fragment reproduces the full pharmacology of the parent hormone. No fatty acid. No engineered protective group. Just the active N-terminal domain of GHRH.

Serono developed it in the 1980s. The FDA approved it in 1997 as Geref for pediatric growth hormone deficiency. In 2008, Serono's successor pulled it from the U.S. market. The reason was commercial. Small patient population, small revenue. It wasn't a safety withdrawal.

For the next decade, U.S. pharmacies could compound sermorelin under prescription. Recent FDA actions have tightened that channel (Mendias & Awan, 2026).

In the GHRH-analog family, sermorelin is the original. Here's the family tree:

• Sermorelin: the unmodified parent. Half-life 10–20 minutes.
• Tesamorelin: adds a fatty-acid tail that blocks an enzyme called DPP-IV. Half-life 26–38 minutes. The only family member with current FDA approval.
• CJC-1295: further structural tweaks for stability.
• CJC-1295 with DAC: adds an albumin-binding group. Half-life jumps to 6–8 days.

Each generation traded duration for complexity. Sermorelin's only modern advantage, if it has one, is that the brief GH elevation it produces more closely resembles native pulsatile secretion than the sustained elevation produced by CJC-1295 with DAC.

How does sermorelin actually work?

Pituitary GH release mechanism

Sermorelin binds the GHRH receptor on anterior pituitary somatotrophs (the cells that produce GH). That binding raises intracellular cAMP, activates protein kinase A, and triggers pulsatile release of stored growth hormone — mirroring the pattern of endogenous GH secretion.

Because sermorelin acts one step upstream of GH, the normal hypothalamic feedback system (somatostatin and rising IGF-1) remains intact and can modulate the response. This is why GHRH analogs have been described in the literature as a more "physiologic" approach than exogenous GH replacement (Memdouh et al., 2021).

Extrapituitary GHRH receptor expression

Early models held that GHRH receptors were confined to pituitary tissue. Subsequent research has identified receptor expression in pulmonary, cardiac, pancreatic, and several tumor-derived cell lines (Condor Capcha et al., 2023; Louzada et al., 2023). The functional significance of these off-target sites in humans remains unclear; available data are primarily from animal models or structurally related analogs rather than from sermorelin itself.

Pancreatic protection (early-stage)

A 2023 PNAS study (mice + human islets) used a sermorelin-like analog called MR-409 in a type 1 diabetes model. The team reported preserved beta-cell mass (the pancreatic cells that make insulin), less cell death, and better insulin secretion (Louzada et al., 2023). It's an analog-adjacent finding. Mechanism-validating, not a human result.

Anti-tumor signal (early-stage)

A 2021 drug-screening study flagged sermorelin as a candidate against recurrent glioma (Chang et al., 2021). Confusingly, GHRH antagonists (drugs that block the same receptor) are being developed as anti-cancer agents too. A 2025 paper showed they make lung cancer cells more sensitive to radiation (Gesmundo et al., 2025). So agonists and antagonists both show activity in different cancers. The honest read: the biology is tissue-specific and the simple narrative "this is a cancer-promoting target" is wrong.

Dosing context in the research literature

No FDA-approved sermorelin product exists today, and no modern RCT has established an adult dose. Historical reference points from the Geref label and published pharmacokinetic studies include:

• Pediatric GHD (Geref label): the approved protocol used approximately 30 mcg/kg subcutaneously once daily in diagnostic and therapeutic studies.
• GH stimulation testing (historical): a single 1 mcg/kg IV bolus with GH measurements at 15, 30, 60, 90, and 120 minutes post-administration was used in diagnostic protocols.
• Adult off-label published literature: compounding pharmacy protocols described in the literature have cited 200–500 mcg subcutaneously once daily. A 2026 review notes these protocols lack RCT validation (Mendias & Awan, 2026).

Because sermorelin acts through the intact hypothalamic–pituitary feedback axis, the cycling rationale applied to exogenous GH (receptor downregulation) is pharmacologically weaker here. No published trial has compared continuous versus intermittent administration protocols.

What does the research actually show?

Here's where the honest story matters. Sermorelin has a longer human track record than almost any other unapproved peptide. It had 11 years of FDA approval (1997–2008). The catch is that the modern adult evidence is empty.

• Pediatric GHD (settled): Geref's FDA approval rested on trials showing sermorelin stimulates GH well enough to diagnose and treat pediatric growth hormone deficiency. The pharmacology is uncontested.
• Adult body composition and anti-aging: 0 RCTs (2020–2026). A 2026 review in Sports Medicine places sermorelin among unapproved peptides where the claimed benefits are mechanism-based, not trial-validated (Mendias & Awan, 2026).
• Pancreatic beta-cell protection: the sermorelin-like analog MR-409 preserved beta-cell mass in mice with streptozotocin-induced diabetes (Louzada et al., 2023). Preclinical, not human.
• Anti-glioma signal: sermorelin came out of a drug-screen for recurrent glioma (Chang et al., 2021). Hypothesis-generating.
• Hypogonadism context: a 2020 narrative review groups sermorelin with other GH-releasing drugs for possible roles in low-testosterone management (Sinha et al., 2020). Conceptual, not interventional.
• Anti-doping detection: labs can reliably detect sermorelin and its metabolite fragments in urine and blood (Memdouh et al., 2021).

Sermorelin

29 aa GHRH 1-29 Parent compound

Sermorelin is on our catalog roadmap — not yet stocked at Peptriva. The closest currently available reference compound in our catalog is tesamorelin, the stabilized GHRH analog cited in the same family of studies in this review. Lab-verified identity and purity.

Browse the catalog

What about stacking?

The only stack with even mechanistic logic is sermorelin plus a GHRP (growth hormone-releasing peptide, a different family that works on a different receptor). The human-outcome evidence is still limited.

Sermorelin combined with ipamorelin (a combination studied in the literature)

Sermorelin acts at the GHRH receptor; ipamorelin acts at the ghrelin receptor. Because the two pathways are independent, the GH responses were hypothesized to be additive. Compounding pharmacy literature has described co-administration of both agents; however, no published controlled trial has confirmed that the combined effect exceeds either agent administered alone.

Sermorelin versus the modern GHRH analogs

In published comparisons, sermorelin has largely been supplanted by later-generation analogs. Tesamorelin carries the only current FDA approval in the class. CJC-1295 offers substantially longer duration of action. The differentiating variable is half-life: sermorelin's approximately 10–20 minute half-life produces a brief, pulse-like GH elevation that more closely resembles endogenous secretion, while longer-acting variants produce a sustained elevation profile. Whether the pulse pattern confers distinct physiological advantages in adult research subjects has not been established in controlled trials.

Reconstitution, handling, and storage

Peptriva supplies sermorelin as a lyophilized (freeze-dried) powder, typically in 2–5 mg vials, for in vitro research use. Standard reconstitution procedure for aqueous stock preparation:

1. Allow the sealed vial to equilibrate to room temperature (15–20 minutes) before opening.
2. Draw the diluent. 2 mL of bacteriostatic water into a 5 mg vial yields a working concentration of 2,500 mcg/mL.
3. Direct the diluent stream slowly down the interior wall of the vial — avoid forceful injection onto the lyophilized cake.
4. Swirl gently to dissolve. Do not vortex or shake; the 29-residue chain is susceptible to mechanical degradation.
5. Allow 1–5 minutes for complete dissolution. The target solution is clear and colorless.
6. Label the vial with preparation date, concentration, and expiry date.

Storage: lyophilized vials are stable at −20 °C for 24+ months. Reconstituted solution should be stored at 2–8 °C and used within 14–28 days. Repeated freeze–thaw cycles compromise peptide integrity.

What are the side effects?

Commonly reported

• Injection-site reactions: brief redness, mild swelling, or itching at the site. The most common effect.
• Transient flushing: warmth or facial flushing within minutes of injection. Usually gone within an hour.
• Mild headache.
• Vivid dreams or altered sleep: GHRH plays a role in deep sleep, so this tracks.

Less commonly reported

• Mild swelling, joint stiffness, tingling: secondary to GH elevation; consistent with effects observed with high-dose GH replacement in published trials.
• Reduced insulin sensitivity: GH is counter-regulatory to insulin; sustained GH elevation has been reported to blunt insulin action in study participants with baseline metabolic risk factors.
• Carpal tunnel-like symptoms: reported in cohorts where IGF-1 remained above the reference range for extended periods.

Rare or theoretical concerns

• Tumor biology: GHRH receptors live in some tumors, and sustained IGF-1 elevation is a theoretical cancer concern for the whole GH-axis class. The picture is complicated. The 2021 drug-screen study showed sermorelin fighting glioma cells (Chang et al., 2021), and GHRH-blocking drugs are being developed as cancer treatments (Gesmundo et al., 2025). The biology runs in both directions.
• Long-term safety data is missing. No controlled long-term safety study exists for modern adult use. That's the honest statement about sermorelin's risk profile in 2026.

What's the legal and FDA status?

The FDA approved sermorelin as Geref in 1997 for pediatric growth hormone deficiency. In 2008, the manufacturer pulled it. It was a commercial decision (small patient pool, low revenue), not a safety withdrawal. No FDA-approved sermorelin product has existed since.

From 2008 on, 503A and 503B compounding pharmacies supplied sermorelin under prescription for off-label use. The FDA has recently tightened that channel (Mendias & Awan, 2026). Research-grade sermorelin remains legal to sell in the U.S. when labeled Research Use Only.

• FDA (U.S.): Geref discontinued 2008. No approved product. Compounding restrictions in place.
• EMA (EU): not approved.
• Health Canada: not approved.
• Research compound sale (U.S.): legal when labeled Research Use Only.

Is sermorelin banned by WADA?

Yes. Sermorelin sits on the WADA Prohibited List in Section S2 (peptide hormones and growth factors). It's banned in and out of competition. Labs detect sermorelin's metabolite fragments using validated mass-spectrometry methods (Memdouh et al., 2021; González-López et al., 2023).

The short half-life does not confer evasion of detection. Published research confirms that metabolite fragments persist after the parent compound is cleared. Sermorelin is prohibited by MLB, NFL, NHL, NBA, FINA, UCI, and NCAA. Validated mass-spectrometric detection methods are documented in the peer-reviewed literature.

Sermorelin

Roadmap ≥99% pure (when stocked) Lyophilized

Sermorelin (GHRH 1-29) is the unmodified parent peptide of the GHRH analog family. It's on Peptriva's catalog roadmap but not yet stocked. The closest available reference compound today is tesamorelin — the stabilized analog with the only currently-FDA-approved indication in the GHRH family. Each lot ships with a third-party CoA from an ISO 17025 lab.

Learn more

Frequently asked questions

What is sermorelin?

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of native growth hormone-releasing hormone (GHRH). It binds GHRH receptors on anterior pituitary somatotrophs and stimulates pulsatile endogenous GH release. The FDA approved it as Geref in 1997 for pediatric growth hormone deficiency. The manufacturer discontinued it in 2008 for commercial reasons.

Is sermorelin FDA-approved?

Not currently. Geref was the approved product. It was discontinued in 2008 for commercial reasons, not safety. Since then, only compounding pharmacies have supplied sermorelin under prescription. The FDA has recently tightened that channel.

How does sermorelin compare to tesamorelin and CJC-1295?

All three act at the same GHRH receptor. Sermorelin is the unmodified parent with a 10–20 minute half-life. Tesamorelin adds a fatty-acid moiety that extends half-life to 26–38 minutes and is the only GHRH analog with current FDA approval (for HIV-associated lipodystrophy). CJC-1295 modifies the scaffold further, and the DAC variant binds albumin for a multi-day half-life.

What dosing has been described in the sermorelin literature?

The Geref pediatric label used approximately 30 mcg per kilogram once daily. Published adult off-label protocols have described 200–500 mcg subcutaneously once daily, timed to align with the natural nocturnal GH pulse. No recent randomized controlled trial supports a specific adult dose for any indication.

Is sermorelin banned by WADA?

Yes. It is on the Prohibited List in Section S2 and banned in and out of competition. Published mass-spectrometric methods can detect sermorelin and its characteristic metabolite fragments in biological samples.

What adverse effects have been reported in studies?

Published reports have described injection-site reactions, transient flushing, mild headache, and altered sleep patterns in study participants. Less commonly reported effects include mild edema, joint stiffness, and changes in insulin sensitivity. Long-term controlled safety data in adults are absent.

Is research-grade sermorelin available in the U.S.?

There is no FDA-approved sermorelin product. Compounding pharmacies have historically supplied it under prescription, though the FDA has tightened that route. Research-grade sermorelin is legal to sell in the U.S. when labeled Research Use Only.